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Summary
Introduction: It is estimated that up to 25% of patients referred to specialised
epilepsy centers suffer from psychogenic non-epileptic seizures (PNES). The prognosis
is unfavourable and there are no generally accepted treatment protocols.
Method: In this study, the effect of an uncontrolled, prospective inpatient treatment
program for PNES patients is evaluated. The treatment is multidisciplinary and based
on cognitive behavioural principles. Seizure control, general psychopathology, anxi-
ety, depression, coping, dissociation and health related quality of life are evaluated.
Twenty-two patients participated in the study of which 16 patients were followed 6
months after treatment.
Results: After follow-up, 81% of patients had a seizure reduction of over 50%, and half
of them became seizure-free. Measures of anxiety, depression and dissociation tended
to normalize, coping was more adequate and health related quality of life was
increased slightly. In the period between the end of treatment and follow-up the
most positive effects are maintained and even strengthened. Patients who became
seizure-free at follow-up improvedmore on the psychological outcomemeasures than
patients with continuing seizures.
Conclusion: The outcome suggests effectiveness of the treatment. PNES patients may
profit from a comprehensive, multidisciplinary treatment program following cognitive
behavioural principles. Seizure cessation appears to be an important factor in the
improvement of psychological functioning.
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Seizures, i.e. paroxysmal, involuntary distur-
bances of controlling motor, sensory, autonomic,
cognitive, emotional or behavioural functions, may
have a serious negative impact on daily life,
whether they result from organic or psychological
origin. When seizures are caused by excessive and
simultaneous electrical discharges of groups of
brain cells it is an epileptic event. If there is no
epilepsy-characteristic electrical brain activity
during the seizure, and no other medical disorders
associated with seizure-like events, the seizures
are considered as a psychological manifestation.1
Several authors emphasize the enormous load of
psychogenic non-epileptic seizures (PNES) patients
within the health service.2,3 The prevalence of
patients with PNES is calculated between 1/3000
and 1/50,000.4 It is estimated that up to 25% of
patients referred to specialised epilepsy centers
suffer from PNES.5 A non-published report from our
centre reveals that about 22% of patients admitted
for seizure diagnosis do have PNES; another 7%
have PNES in combination with epilepsy.
The time between the age at onset of seizures and
the correct diagnosis is often several years6 andmany
patients are treated with ineffective and potentially
toxic anti-epileptic drugs (AEDs), also experiencing
the negative psychological and socio-economic con-
sequences of carrying a diagnosis of epilepsy.
There is no evidence that suffering from PNES
refers to a unified pathological syndrome or a deter-
mined aetiology.7 Bowman and Markand8 propose
four pathways to the development of PNES, namely
a history of childhood physical or sexual abuse,
recent sexual assault, multiple life stresses that
overwhelmed the patients’ coping abilities, and
panic attacks mistaken for PNES. This implies that
the specificity of any treatment protocol for PNES
patients can only be moderate and that treatment
programs need to be individualised.9
An effective treatment, leading to long-term
seizure freedom and a normalized quality of life
does not yet exist. Several psychological interven-
tions are described, such as cognitive behavioural
therapy, group psycho-education, psychotherapy,
eye movement desensitization and a combination
of psychological interventions10—14 (for reviews also
see Refs. 7,15,16). In general, the prognosis is unfa-
vourable15 and seems dependent on factors such as
an early diagnosis, psychiatric comorbidity, an acute
trauma preceding the onset of seizures, and the
duration of seizure history.9,17,18
LaFrance et al.7,15 reviewed PNES treatment stu-
dies and concluded that higher success rates in PNES
outcome studies were found in longer inpatientadmissions and in cases where patients were man-
aged by a multidisciplinary team familiar with PNES.
McDade and colleagues14 show in an uncontrolled
inpatient outcome study a cessation of seizures in
50% of patients (n = 16), a decrease of seizure fre-
quency in 19% and no change in 31% of patients after
a follow-up of 12 months. Kim et al.19 evaluated an
inpatient treatment program in 14 patients and
concluded that 79% experienced either a significant
improvement or complete cessation of seizure
activity. An inpatient outcome study by Rush
et al.9 showed that patients with a mean duration
of seizures of less than 12 months were seizure-free
after treatment, while from patients with a longer
existent history of seizures, 60% (n = 15) were sei-
zure-free after treatment, suggesting that a longer
history of seizures brings about poorer treatment
outcome.
In PNES treatment studies, the most frequently
reported outcome measure is the change in seizure
frequency. One study20 showed however that sei-
zure cessation rather than seizure reduction results
in a better functional outcome. Another study21
revealed that seizure-free patients may continue
to have symptoms of psychopathology, remain
unproductive and dependent on social assistance,
suggesting that seizure freedom should not be the
only focus of treatment.
In this paper, the outcome of an uncontrolled
prospective study of the efficacy of an open psy-
chotherapeutic inpatient treatment program is
described. The program is individualised and
adjusted to the patients’ individual needs. The
program, consisting of individual and group thera-
pies, focuses on seizure control as well as to the
improvement of psychological functioning and psy-
chological well-being.
In this paper, we evaluate seizure frequency,
health related quality of live (HRQOL), anxiety,
depression, coping and dissociation at the beginning
and completion of the treatment, and after a fol-
low-up period of 6 months. To evaluate the rele-
vance of seizure cessation versus seizure reduction,
a comparison of these outcome variables will be
made between seizure-free patients and patients
who were not seizure-free at follow-up. Addition-
ally, the effect of the treatment program will be
investigated in each subgroup separately.Method
Patients and procedure
The treatment program is offered in a special
unit of the Epilepsy Institute of The Netherlands
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PNES patients can be admitted after the diagnosis
‘no epilepsy’ is made by the neurologist (based on
one or more EEG-confirmed typical seizures).
Patients are informed that the seizures are not
epileptic and cannot be attributed to other med-
ical conditions. They then receive information
about the possibilities of treatment. If they agree
with admission, the program in the first 4 weeks is
mainly focussed on the psychological diagnostic
process. Assessment of patients’ skills, abilities,
psychopathology, and family dynamics is per-
formed to generate a working hypothesis concern-
ing the underlying problems which may cause and
maintain the seizures, and to provide the patient
with an acceptable explanation of the seizures.
Patients are actively involved in this process and
this helps them to make the switch from a neu-
rological to a psychological interpretation of their
seizures. Following the diagnostic phase, a multi-
disciplinary treatment is offered based on cogni-
tive behavioural principles. The treatment is
aimed at cognitive restructuring, trauma treat-
ment, stimulus differentiation, coping skills,
stress management and includes individual and
group therapies. Treatment includes individual
psychotherapy, psychomotor and creative therapy,
family therapy and participation in the following
group therapies: assertivity training, rational
emotive therapy and training in behavioural
analysis. During the weekends the unit is closed
and patients go home in order to facilitate
the integration of learned skills in their natural
environment.
PNES patients who entered this study were
admitted to SEIN’s psychotherapeutic treatment
unit in the period June 2002 to December 2004.
Twenty-nine patients agreed to participate, of
whom 3 patients stopped treatment prematurely
(2 patients because of private reasons and 1
patient disagreed with the treatment plan and left
the clinic). This resulted in 26 patients who were
included in the study, of which 4 patients suffered
from PNES as well as epileptic seizures. These
‘mixed-seizure’ patients were excluded from the
analysis because PNES and epileptic seizures are
not always easy to discern from each other. Also,
there are indications that the psychiatric profile
of this patient group differs from PNES-only
patients.22
In all patients, the seizure diagnosis was based on
EEG/video-registration of one or more typical sei-
zures. At the start of treatment (T1) and at dis-
charge (T2), psychological data were gathered and
seizure frequency was observed. The samewas done
after 6 months (T3). At the time of follow-up, 3patients were untraceable and 3 patients withdrew
from the study.
Measures
Seizure frequency was observed and counted at the
time of T1 and T2 by the nursing staff, and at T3
reported by the patients themselves. At T1 and T2
the average seizure frequency per week for the
period of the last 3 weeks was registered, and at
T3 the mean frequency per week over the last 4
weeks. At T3 self-reported measures of seizure
duration and the feeling of seizure control were
collected. Also, the number of anti-epileptic med-
ication taken by the patients at T1, T2 and T3 was
recorded.
The following questionnaires were used as
outcome variables: the Symptom Checklist-90
(SCL-90),23,24 a multi-dimensional index of psycho-
pathology; the Beck Depression Inventory (BDI), a
short self-report questionnaire assessing the
degree of depression25,26; the State-Trait Inventory
(STAI),27,28 a self-report measure of subjective
state and trait anxiety; the Utrecht Coping List
(UCL),29 a Dutch questionnaire measuring coping
behaviour; the SF-36,30,31 measuring self-per-
ceived health related quality of life; the Dissocia-
tion Questionnaire (DISQ),32 measuring self-
reported daily dissociative experiences.
Statistical analysis
Data were analyzed using SPSS for Windows release
14. Change in outcome measures was evaluated
with the Wilcoxon Matched Pairs Signed Rank test
because data were not normally distributed.
Pearson’s correlations are calculated to measure
the relation between outcome variables and seizure
frequency. Fisher’s Exact tests are used when com-
paring seizure-free patients and patients with
ongoing seizures.Results
Patient characteristics
Demographic data are shown in Table 1. In 13 PNES
patients the diagnosis PNES was made just before
admission. The time between the diagnosis and start
of the treatment for the other patients varied from
3.5 to 12 months (mean 6.7 months).
The duration of the program varied from 2 to 6
months with an average of 4.8 months. The mean
duration of pre-treatment seizures was 6.7 years
(median 4.5 year, range 0—24 years).
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Table 1 Patient characteristics
Sex (%) Female/male 77.3/22.7
Age (years) Mean (S.D.) 30.6 (10.8)
Range 19—52
Marital status (%) Married/living together 40.9
Single 59.1
Occupation (%) Housekeeping 9.1
Employment 54.5
Disability pension/welfare 27.3
Other 9.1
Education (%) Primary education 13.6
Secondary education 72.8
Higher education 13.6
Age at onset seizures (years) Mean (S.D.) 23.9 (11.3)
Range 8—52
Duration of seizures (years) Mean (S.D.) 6.7 (7.2)
Range 0—29Outcome measures
Seizures
Changes in seizure frequency at T2 and T3 are shown
in Table 2. Mean seizure frequency a week at T2 and
T3 decreased significantly with respect to the pre-
vious measurement. Two patients had no seizures in
the period of 3 weeks before T1. At T2 another 4
patients were seizure-free. After 6 months, 7
patients (44%) of the 16 responders reported no
seizures during the last 4 weeks, one of whom
reported no seizures at T1. In another 6 patients
(37.5%) the seizure frequency declined more than
50%. An increase in seizures was experienced by 2
patients.
At follow-up, 6 patients (67%) with ongoing sei-
zures reported less serious seizures than before, 5
(56%) reported that their seizures were of shorter
duration, and 7 patients (81%) reported increased
control over their seizures.
Anti-epileptic medication
On admission, AEDs were taken by 63.6% of patients
(8 patients 1 AED, 6 patients 2 AEDs). After treat-
ment, 2 patients received 1 AED: lamotrigine wasTable 2 Seizure frequency per week at T1 (start of treatm
T1 (n = 22) T2 (n = 22) T3 (n = 16)
Mean (S.D.) 6.6 (9.8) 3.0 (4.7) 0.9 (1.8)
Median 2.5 0.8 0.3
Range 0—36 0—19 0—11
No seizures 7.7% 27.3% 44%
Decrease >50%b 40.9% 37.5%
Decrease <50%b 18.2% 6.2%
Increaseb 14% 12.5%
a Wilcoxon Matched Pairs Signed Rank, two tailed test.
b Change in seizure frequency on T2 and T3 compared with T1.prescribed to 1 patient as a precaution because he
had paroxysmal EEG abnormalities (which did not
correlate with seizure-like manifestations), another
patient received valproate for complaints of
migraine. At T3 anti-epileptic medication was not
changed: 14 patients received no AEDs, 2 patients
received 1 AED for reasons mentioned above.
Psychological questionnaires
In Table 3 mean scores are shown in all psychological
questionnaires. Patients showed improvements
between T1 and T2 on the BDI, STAI-trait, UCL-
active and dissociation scores. After follow-up,
the improvement seems to increase as the mean
scores on all measures decreased. On the SCL-90 and
DISQ, significant improvements were found on all
subscales. The mean score at T1 on the SCL-90 is
relatively high (percentile 97). On T2 the mean
scores drop to percentile 87 and on T3 to percentile
69. Mean BDI-scores are located in the ‘mild to
moderate’ severity categories and decrease on T2
and T3 to the minimal depressed category. STAI-
anxiety scores are situated in the 8th to 9th decile at
T1, in the 7th decile at T2 and in the 4th to 5th
decile at T3.ent), T2 (end of treatment) and T3 (follow-up)
za ( p) T1 vs. T2 za ( p) T2 vs. T3 za ( p) T1 vs. T3
2.33 (0.02) 1.99 (0.05) 3.12 (0.002)
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Table 3 Outcome measures on start of treatment (T1), end of treatment (T2) and follow-up (T3)
T1 (n = 22)
mean (S.D.)
T2 (n = 22)
mean (S.D.)
T3 (n = 16)
mean (S.D.)
za ( p) T1
vs. T2
za ( p) T2
vs. T3
za ( p) T1
vs. T3
SCL-90 178.7 (57.3) 155.9 (58.5) 135.1 (37.4) 1.53 (.12) 1.03 (.30) 3.00 (.003)
BDI 19.7 (9.4) 11.5 (10.9) 9.2 (7.5) 3.01 (.003) 1.08 (.28) 3.47 (.001)
STAI-state 46.1 (11.9) 40 (11.8) 33.3 (9.1) 1.63 (.10) 1.37 (.17) 3.05 (.002)
STAI-trait 47.2 (10.9) 41.2 (10.9) 36.7 (10.1) 2.17 (.03) 0.83 (.41) 2.33 (.02)
UCL-active 34.6 (8.1) 39 (6.2) 40.3 (5.9) 2.52 (.01) 0.31 (.75) 2.11 (.03)
UCL-passive 63.5 (6.9) 60.3 (10.3) 57.1 (6.9) 1.01 (.31) 0.85 (.39) 2.59 (.01)
DISQ 1.86 (0.37) 1.69 (0.42) 1.48(0.17) 1.99 (.05) 0.80 (.42) 2.59 (.01)
a Wilcoxon Matched Pairs Signed Rank, two tailed test.Quality of life
HRQOL scores on the SF-36 are shown in Table 4. No
significant changes are found after treatment at T2.
At T3 better scores are obtained in comparison to T1
on the dimension ‘role limitation due to emotional
problems’.
Seizure frequency, psychopathology and
HRQOL
At follow-up, seizure frequency for the whole group
showed two significant correlations on the outcome
measures: patients with more seizures showed less
active coping abilities (r = 0.52; p = 0.039), and
had a poorer outcome on the HRQOL dimension
‘energy vitality’ of the SF-36 (r = 0.56; p = 0.025).
Seven patients had no seizures at T3 and 9
patients reported still having seizures at follow-
up. Prior to treatment, both groups did not differ
on the patient characteristics and on the outcome
measures.
Table 5 shows the changes between T1 and T3 in
both groups. Compared to patients with ongoing
seizures, seizure-free patients showed improve-
ments on all psychological questionnaires, except
for passive coping and dissociation. Although all
scores on the HRQOL dimension improved withinTable 4 Health related quality of life as measured on the SF
follow-up (T3)
SF36 T1 (n = 19) T2 (n = 19) T3 (n
Physical functioning 78.2 80.8 76.3
Role limitation due to
physical problems
47.2 66.7 51.7
Role limitation due to
emotional problems
55.6 81.5 84.4
Social functioning 55.6 60.8 68.9
Mental health 62.5 69.3 74.1
Energy vitality 56.8 59.5 54.7
Pain 58.5 68.4 65.2
General health perception 54.9 65.2 60.0
Change in health 53.9 63.2 65.0
a Wilcoxon Matched Pairs Signed Rank, two tailed test.the seizure-free group compared to T1, no signifi-
cant differences were found. Patients with continu-
ing seizures improved on general psychopathology,
depression and passive coping.
A comparison between seizure-free patients and
those not seizure-free on the outcome measures at
T3 is shown in Table 6. Seizure-free patients showed
significantly less general psychopathology, depres-
sion, anxiety and dissociation, and a better active
coping than patients with ongoing seizures. Also, the
level of the HRQOL dimensions ‘mental health’,
‘energy vitality’ and ‘pain’ were improved on the
SF-36, compared to those patients who continued to
have seizures.Discussion
The aim of this study was to evaluate the outcome of
an open inpatient treatment program for PNES
patients. The overall results suggest that patients
profited from the treatment and that positive
effects were maintained, and even strengthened,
during the follow-up period. The positive effects of
treatment were supported by a significant decrease
in seizure frequency and decreased scores on mea--36 at start of treatment (T1), end of treatment (T2) and
= 15) za( p) T1 vs. T2 za( p) T2 vs. T3 za( p) T1 vs. T3
0.84 (.40) 1.17 (.24) 0.53 (.59)
1.74 (.08) 1.31 (.19) 0.27 (.78)
1.86 (.06) 0.32 (.75) 2.21 (.03)
0.87 (.38) 0.90 (.92) 1.68 (.09)
1.60 (.11) 1.34 (.18) 1.91 (.06)
0.45 (.65) 1.14 (.25) 0.60 (.55)
1.45 (.15) 0.77 (.44) 0.71 (.48)
1.85 (.06) 1.65 (.10) 0.94 (.35)
1.22 (.22) 0.89 (.89) 1.53 (.13)
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Table 5 Changes in scores on the psychological questionnaires between T1 and T3 in seizure-free and not seizure-
free patients
Seizure-free (n = 7) mean (S.D.) Not seizure-free (n = 9) mean (S.D.)
T1 T3 p a T1 T3 p a
SCL-90 176.9 (70.3) 110.1 (11.9) 0.016 185.7 (56.1) 154.4 (39.3) 0.039
BDI 15.3 (9.6) 4.7 (3.1) 0.031 21.7 (10.0) 12.7 (8.1) 0.004
STAI-state 46.0 (12.9) 28.3 (7.8) 0.031 45.3 (12.1) 37.2 (8.4) 0.055
STAI-trait 44.0 (12.8) 30.6 (6.1) 0.031 47.9 (10.1) 41.6 (10.1) 0.36
UCL-active 32.6 (7.6) 42.7 (5.5) 0.031 38.3 (8.4) 38.4 (5.8) 0.69
UCL-passive 63.1 (9.1) 54.9 (8.2) 0.22 64.1 (6.1) 58.8 (5.8) 0.02
DISQ 1.75 (0.15) 1.33 (0.09) 0.12 1.87 (0.40) 1.56 (0.15) 0.08
SF36 Seizure-free (n = 6) mean (S.D.) Not seizure-free (n = 9) mean (S.D.)
T1 T3 p a T1 T3 p a
Physical functioning 85.0 (13.4) 90.7 (8.3) 0.37 78.3 (14.4) 65.6 (32.2) 0.28
Role limitation due to
physical problem
62.5 (49.4) 75.0 (38.2) 0.75 44.4 (39.1) 38.9 (39.7) 0.93
Role limitation due to
emotional problem
77.8 (27.2) 95.2 (12.6) 0.50 48.1 (44.4) 77.8 (33.3) 0.12
Social functioning 48.1 19.4) 79.4 (20.7) 0.06 59.2 (19.2) 62.9 (15.7) 0.70
Mental health 68.7 (21.1) 83.4 (11.2) 0.22 60.4 (17.7) 68.9 (14.9) 0.18
Energy vitality 56.7 (19.7) 77.1 (16.3) 0.09 47.8 (20.2) 41.7 (22.8) 0.40
Pain 61.1 (28.8) 79.4 (28.3) 0.25 60.5 (17.7) 54.3 (22.5) 0.72
General health perception 46.8 (21.5) 69.6 (29.0) 0.22 54.7 (17.6) 53.9 (19.1) 0.73
Change in health 62.5 (20.9) 78.6 (26.7) 0.25 44.4 (16.7) 52.8 (31.7) 0.48
a Fisher Exact test.sures of anxiety, depression, dissociation and an
improvement of coping abilities. Six months after
discharge, 80% of patients had a seizure reduction of
over 50%, and half of them was seizure-free. With
regard to HRQOL, PNES patients improved slightly onTable 6 Outcome at T3 in patients who are seizure-free a
Seizure-free (n = 7) mean (S.D.)
SCL-90 110.2 (11.9)
BDI 4.7 (3.1)
STAI-state 28.3 (7.8)
STAI-trait 30.6 (6.1)
UCL-active 42.7 (5.5)
UCL-passive 54.9 (8.2)
DISQ 1.3 (0.09)
SF36 Seizure-free (n = 6) mean (S
Physical functioning 90.7 (8.4)
Role limitation due to
physical problems
75.0 (38.2)
Role limitation due to
emotional problems
96.2 (12.6)
Social functioning 79.4 (20.7)
Mental health 83.4 (11.2)
Energy vitality 77.1 (16.3)
Pain 79.4 (28.3)
General health perception 69.6 (29.0)
Change in health 78.6 (26.7)
a Fisher Exact test.domains concerned with mental functioning. A
decrease in the use of anti-convulsive medication
— from 63.6% of patients at admission to 9% at
follow-up — may indicate that the treatment brings
about a reduction of costs to medical healthnd those who are not
Not seizure-free (n = 9) mean (S.D.) p a
154.4 (39.3) 0.011
12.7 (8.1) 0.024
37.22 (8.4) 0.056
41.6 (10.1) 0.024
38.4 (5.8) 0.048
58.8 (5.8) 0.24
1.6 (0.15) 0.044
.D.) Not seizure-free (n = 9) mean (S.D.) p a
65.6 (32.1) 0.11
38.9 39.7) 0.12
77.8 (33.3) 0.34
62.9 (15.7) 0.21
68.9 (14.9) 0.04
41.7 (22.8) 0.004
54.3 (22.5) 0.05
53.9 (19.1) 0.11
52.8 (31.7) 0.12
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anxiety scores before treatment were increased
compared to norms of the healthy population. After
treatment and follow-up, the level of general psy-
chopathology was considerably lower, depression
was in the minimal range and anxiety was nearly
normalized.
Although our results seem in line with other inpa-
tient treatment studies, post-treatment seizure con-
trol in our study is difficult to compare with other
inpatients treatment studies, due to differences in
several patient characteristics. For example, in the
Rush study,9 65% of patients were seizure-free after a
6 months follow-up, but most seizure-free patients
had a PNES history of less than 12 months, which is
considered as a favourable prognostic factor. In our
study only 1 patient had a seizure history of less than
12 months and the mean seizure duration was 6.7
years. Patients with comorbid epilepsy participated
in the studies of Rush9 and Kim.19 We excluded them
because it was not possible to determine the seizure
frequency in a reliable way. McDade14 also included
patients with an IQ < 80 and found a significant
associationbetween low IQandoutcome. In our study
patients with an IQ < 80 were excluded from treat-
ment at this unit.
Several studies emphasize the importance of
seizure cessation rather than a freedom from
them.20,21 Reuber et al. showed that seizure cessa-
tion is not a sufficient condition for a good psycho-
social outcome in PNES patients, while some of them
continue to report symptoms of psychopathology
and remain unproductive.21 In our series, however,
psychopathology in seizure-free patients tended to
normalize. In patients with continuing seizures, the
level of psychopathology improved slightly. The
seizure-free group profited more from the treat-
ment than those patients who did not become sei-
zure-free. As psychological well-being seems to be
related to seizure cessation, seizure freedom has to
be an important goal in the treatment of PNES
patients.
Surprisingly, the HRQOL seems to improve only to
some extent, despite the improvements in seizure
frequency and psychopathology. The exact reason
for this result is not quit clear; a replication of our
study with more patients may provide more clarity.
Considering, however, the long time that most
patients were treated as having epilepsy (average
of 6.7 years), it can be speculated that the medical
diagnosis of epilepsy before correct diagnosis and
appropriate treatment of PNES, might have long
(psychosocial) after-effects. Therefore, in future
studies, it seems of importance to evaluate the
effect of treatment on psychosocial factors for a
longer time than 6 months.The first 4 weeks of the program are mainly
focused on the psychological diagnostic process.
In our opinion, this is an important part of the
treatment: patients have the opportunity to gradu-
ally get accustomed to the idea that their problem is
not somatic but has a psychological origin and, at
the same time, experience that their seizures are
being taken very seriously. The patients start ‘blank’
(we only know it is not epilepsy), and together with
the patient and family we try to understand and
explain the background of the seizures. Our experi-
ence with this diagnostic program has been that
patients are less inclined to return to a somatic
interpretation of the seizures.
This study has several limitations. First, it con-
cerns a small number of patients, which limit solid
conclusions. Also, it did not follow a randomized
controlled design. We cannot exclude that the inpa-
tient nature of treatment may have resulted in a
reduction of stress levels and enhancement of psy-
chological functioning without any further treat-
ment. However, in PNES patients we feel that the
most suitable moment to start treatment is when
the patient is informed about the seizure diagnosis.
It is believed that telling the diagnosis is the first
step in treatment33 and a longer delay between
diagnosis and treatment may intensify psychological
resistance to the diagnosis and the willingness to be
treated. Another problem of randomization is the
necessity of a control group, often a waiting list
group, or a group treated with ‘neutral’ interven-
tions. It cannot be excluded that, for example, a
delay in treatment can have negative consequences
for the course of the seizure disorder or that dis-
appointment in being assigned to a waiting list group
is a negative and uncontrolled factor.34 Another
difficulty in performing a randomized design is the
heterogeneity of PNES patients: several underlying
causes are assumed and the psychiatric comorbidity
is variable. For this reason, several authors advo-
cate that treatment programs need to be individua-
lised based on aetiology, level of intelligence, family
dynamics, comorbid psychiatric illness and other
factors.9 Possibly, for these reasons controlled
treatment effect-studies in PNES patients are scarce
and literature about treatment concern mostly case
reports or case series (for reviews see Refs. 7,15). A
recent Cochrane review by Baker and colleagues16
found only three controlled randomized studies.
These studies however concerned ‘conversion’
patients, of whom some suffered from PNES.
Our patient group was a selected group, namely,
those patients who accepted the inpatient program.
Moreover, other patients were not asked or not
accepted for treatment. In the study period, 45
patients with the diagnosis PNES were not admitted
602 J. Kuyk et al.to the treatment unit. Eleven of themwere referred
back to their own doctors and 6 patients were
referred to external ambulatory treatment, often
because hospitalization was not possible because of
private reasons. Severe psychiatric comorbidity was
observed in 6 and somatic problems in 3 patients.
This was seen as contra-indication for treatment.
Two patients had an IQ lower than 80 points and 1
patient could not express herself in the Dutch lan-
guage. Sixteen patients refused treatment (8
patients disputed the diagnosis; 2 patients stopped
admission after the diagnosis and 6 patients wished
to seek treatment elsewhere). There is therefore
probably a question of inclusion bias with regard to
this study. There is some evidence that long-term
seizure control depends more on the presence or
absence of underlying psychiatric diagnoses than it
does on treatment,35 so it cannot be excluded that
relatively ‘easy’ patients participated in this study.
The duration of this inpatient treatment program
is at average 4.8 months and therefore costly.
LaFrance et al. note in their reviews that longer
inpatient multidisciplinary treatment show higher
success rates7,15 crucial for treatment success is
acceptation of the diagnosis and recognition of a
psychological explanation for the seizures by the
patient and relatives. The changeover from a med-
ical to a psychological attitude to treatment is
essential and often difficult for the patient and their
environment. In our opinion, this can be at best
achieved by ‘striking the iron when it is hot’ by
starting an extensive inpatient treatment immedi-
ately after PNES is diagnosed. It is conceivable that,
if these conditions are met, outpatient continuation
of treatment may be effective. To the best of our
knowledge, however, no research has been done yet
to investigate the effects of such a combined in- and
outpatient treatment program, but the develop-
ment of such a program seems opportune.Conclusion
In conclusion, our data suggest that there are useful
psychological treatments for PNES patients and that
they may profit from a comprehensive, multidisci-
plinary, inpatient treatment program following cog-
nitive behavioural principles. Our treatment
resulted not only in a decrease of seizures, but also
in a decrease of general psychopathology, anxiety,
depression and dissociation, and an increase in
coping abilities. This applies for seizure-free
patients more strongly than for patients with
ongoing seizures after treatment, implying that
seizure cessation should be an important focus of
treatment.Acknowledgments
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